1. Three vs. 10 days of amoxycillin–clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study 
B.M. Roede, P. Bresser, R. El Moussaoui, F.H. Krouwels, B.T.J. van den Berg, P.M. Hooghiemstra, C.A.J.M. de Borgie, P. Speelman, P.M.M. Bossuyt, J.M. Prins 
Clinical Microbiology and Infection 
Volume 13, Issue 3, Pages (March 2007)
DOI: /j x
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Trial profile (COPD, chronic obstructive pulmonary disease; co-amoxyclav, amoxycillin-clavulanic acid).
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
Symptom scores for both treatment groups. The symptom scores of both treatment groups are expressed as medians and inter-quartile ranges. Day –30 represents the pre-exacerbation level; day 0 is the day of starting antibiotic therapy; day 21 is test of cure.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig. 3 Clinical success in the intention-to-treat population.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2007 European Society of Clinical Infectious Diseases Terms and Conditions